Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Shares Sold by Strs Ohio

Strs Ohio reduced its stake in shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) by 11.6% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 78,700 shares of the company’s stock after selling 10,300 shares during the period. Strs Ohio owned 0.18% of Y-mAbs Therapeutics worth $536,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. China Universal Asset Management Co. Ltd. acquired a new position in shares of Y-mAbs Therapeutics during the 4th quarter worth approximately $34,000. SG Americas Securities LLC acquired a new position in shares of Y-mAbs Therapeutics during the 3rd quarter worth approximately $100,000. Exchange Traded Concepts LLC boosted its holdings in shares of Y-mAbs Therapeutics by 29.4% during the 3rd quarter. Exchange Traded Concepts LLC now owns 20,971 shares of the company’s stock worth $114,000 after purchasing an additional 4,763 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Y-mAbs Therapeutics by 4.4% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 26,090 shares of the company’s stock worth $178,000 after purchasing an additional 1,089 shares during the last quarter. Finally, Sapient Capital LLC acquired a new position in Y-mAbs Therapeutics in the fourth quarter valued at approximately $298,000. 70.85% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research firms recently commented on YMAB. Canaccord Genuity Group upped their price objective on Y-mAbs Therapeutics from $22.00 to $26.00 and gave the company a “buy” rating in a report on Monday, March 4th. HC Wainwright upped their price objective on Y-mAbs Therapeutics from $21.00 to $22.00 and gave the company a “buy” rating in a report on Wednesday, March 6th. Wedbush reiterated an “outperform” rating and issued a $18.00 price objective (up from $12.00) on shares of Y-mAbs Therapeutics in a report on Monday, February 12th. Finally, BMO Capital Markets upped their price objective on Y-mAbs Therapeutics from $16.00 to $26.00 and gave the company an “outperform” rating in a report on Monday, March 4th. Two investment analysts have rated the stock with a sell rating and four have given a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $16.57.

Y-mAbs Therapeutics Stock Down 0.9 %

NASDAQ:YMAB opened at $14.71 on Friday. The stock’s fifty day moving average is $15.74 and its two-hundred day moving average is $10.51. Y-mAbs Therapeutics, Inc. has a 52 week low of $4.60 and a 52 week high of $20.90. The stock has a market capitalization of $644.00 million, a price-to-earnings ratio of -30.02 and a beta of 0.74.

Y-mAbs Therapeutics (NASDAQ:YMAB) last released its quarterly earnings results on Thursday, February 29th. The company reported ($0.02) EPS for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.17. Y-mAbs Therapeutics had a negative return on equity of 20.72% and a negative net margin of 25.26%. The company had revenue of $23.36 million for the quarter, compared to analysts’ expectations of $21.72 million. On average, sell-side analysts expect that Y-mAbs Therapeutics, Inc. will post -0.43 EPS for the current fiscal year.

Insiders Place Their Bets

In other Y-mAbs Therapeutics news, SVP Vignesh Rajah sold 1,711 shares of the company’s stock in a transaction on Tuesday, March 5th. The stock was sold at an average price of $16.53, for a total transaction of $28,282.83. Following the transaction, the senior vice president now directly owns 33,889 shares in the company, valued at $560,185.17. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 21.50% of the stock is owned by insiders.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.